HK1202527A1 - Compounds for treating spinal muscular atrophy - Google Patents
Compounds for treating spinal muscular atrophyInfo
- Publication number
- HK1202527A1 HK1202527A1 HK15102837.6A HK15102837A HK1202527A1 HK 1202527 A1 HK1202527 A1 HK 1202527A1 HK 15102837 A HK15102837 A HK 15102837A HK 1202527 A1 HK1202527 A1 HK 1202527A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treating spinal
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261614932P | 2012-03-23 | 2012-03-23 | |
PCT/US2013/031232 WO2013142236A1 (en) | 2012-03-23 | 2013-03-14 | Compounds for treating spinal muscular atrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202527A1 true HK1202527A1 (en) | 2015-10-02 |
Family
ID=49223223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102837.6A HK1202527A1 (en) | 2012-03-23 | 2015-03-19 | Compounds for treating spinal muscular atrophy |
Country Status (11)
Country | Link |
---|---|
US (1) | US9914722B2 (xx) |
EP (1) | EP2828247B1 (xx) |
JP (1) | JP6219921B2 (xx) |
KR (1) | KR102109992B1 (xx) |
CN (1) | CN104470909B (xx) |
BR (1) | BR112014023483B1 (xx) |
CA (1) | CA2868026C (xx) |
EA (1) | EA028382B1 (xx) |
HK (1) | HK1202527A1 (xx) |
MX (1) | MX358514B (xx) |
WO (1) | WO2013142236A1 (xx) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
PL2809322T3 (pl) | 2012-01-26 | 2019-11-29 | Ptc Therapeutics Inc | Związki do leczenia zaniku mięśni pochodzenia rdzeniowego |
MX354074B (es) | 2012-02-10 | 2018-02-12 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
BR112014021531B1 (pt) | 2012-03-01 | 2022-10-04 | Ptc Therapeutics, Inc. | Composto, composição farmacêutica e usos dos mesmos |
US10987370B2 (en) * | 2012-12-24 | 2021-04-27 | Ramot At Tel-Aviv University Ltd. | Methods of inducing read-through of a nonsense mutation associated with ataxia telangiectasia, Rett syndrome or spinal muscular atrophy by erythromycin or azithromycin |
RU2016109324A (ru) | 2013-08-19 | 2017-09-26 | Ф. Хоффманн-Ля Рош Аг | Способ скрининга |
EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
WO2016196386A1 (en) | 2015-05-30 | 2016-12-08 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
AU2016284654B9 (en) | 2015-06-26 | 2020-05-21 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
US11702646B2 (en) | 2016-11-28 | 2023-07-18 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
EA201992878A1 (ru) | 2017-06-05 | 2020-05-08 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни хантингтона |
CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
BR112019027717A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
WO2019168170A1 (ja) * | 2018-03-02 | 2019-09-06 | 国立大学法人 長崎大学 | クロモン誘導体及びアミロイド関連疾患診断用組成物 |
CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH479607A (de) * | 1967-02-27 | 1969-10-15 | Geigy Ag J R | Verfahren zur Herstellung von Areno-oxazinonverbindungen |
US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
GB1296469A (xx) * | 1970-02-05 | 1972-11-15 | ||
US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
US5278174A (en) * | 1990-06-04 | 1994-01-11 | Scios Nova, Inc. | Sigma binding site agents |
AU4231293A (en) | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
ATE169924T1 (de) | 1993-05-18 | 1998-09-15 | Takeda Chemical Industries Ltd | Benzopyran-derivate und ihre verwendung |
US5597922A (en) | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
AU5991699A (en) | 1998-09-21 | 2000-04-10 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
ATE363471T1 (de) | 2000-01-24 | 2007-06-15 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
AU2003237492A1 (en) | 2002-06-10 | 2003-12-22 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
CA2495661C (en) | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
CN100430389C (zh) * | 2002-08-16 | 2008-11-05 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
US20040105849A1 (en) * | 2002-11-25 | 2004-06-03 | Kaloidis Antonia C. | Treatment for SMA disease |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
JP2007520435A (ja) | 2003-06-20 | 2007-07-26 | カイロン コーポレイション | 抗癌剤としてのピリジノ[1,2−a]ピリミジン−4−オン化合物 |
AU2004289303A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
US20080255162A1 (en) | 2004-05-04 | 2008-10-16 | Warner-Lambert Company Llc | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents |
US7846915B2 (en) * | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
EP1846397A1 (en) | 2005-01-21 | 2007-10-24 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors |
US20090123563A1 (en) * | 2005-02-07 | 2009-05-14 | Novo Nordisk A/S | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand |
AU2006275514B2 (en) * | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
WO2008013997A2 (en) | 2006-07-27 | 2008-01-31 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
PT2045247E (pt) | 2007-09-14 | 2015-06-09 | Naturewise Biotech & Medicals Corp | Compostos para a inibição da histona-desacetilase |
US8008344B2 (en) | 2007-09-14 | 2011-08-30 | NatureWise Biotech and Medicals Corporation | Compounds for the inhibition of histone deacetylase |
PT2268628E (pt) | 2008-03-06 | 2012-06-28 | Rottapharm Spa | Derivados de 2-aril e de 2-heteroaril 4h-1-benzopiran-4-ona- 6-amidino para o tratamento de artrite, cancro e dores relacionadas |
WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
US20120010178A1 (en) * | 2008-10-21 | 2012-01-12 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
CN101851220A (zh) * | 2009-04-03 | 2010-10-06 | 彦臣生技药品股份有限公司 | 异戊二烯类黄酮化合物及其用途 |
CA2779073C (en) * | 2009-10-30 | 2017-10-24 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
MY173795A (en) | 2009-11-05 | 2020-02-24 | Incozen Therapeutics Pvt Ltd | Novel benzopyran kinase modulators |
WO2011062853A1 (en) | 2009-11-20 | 2011-05-26 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
AU2011206761A1 (en) | 2010-01-13 | 2012-07-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti - infective pyrido (1,2 -a) pyrimidines |
US20130096160A1 (en) | 2010-04-14 | 2013-04-18 | Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
MY168757A (en) | 2011-05-04 | 2018-12-04 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
PL2809322T3 (pl) | 2012-01-26 | 2019-11-29 | Ptc Therapeutics Inc | Związki do leczenia zaniku mięśni pochodzenia rdzeniowego |
MX354074B (es) | 2012-02-10 | 2018-02-12 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
BR112014021531B1 (pt) | 2012-03-01 | 2022-10-04 | Ptc Therapeutics, Inc. | Composto, composição farmacêutica e usos dos mesmos |
-
2013
- 2013-03-14 US US14/386,524 patent/US9914722B2/en active Active
- 2013-03-14 BR BR112014023483-3A patent/BR112014023483B1/pt active IP Right Grant
- 2013-03-14 KR KR1020147029409A patent/KR102109992B1/ko active IP Right Grant
- 2013-03-14 JP JP2015503291A patent/JP6219921B2/ja active Active
- 2013-03-14 WO PCT/US2013/031232 patent/WO2013142236A1/en active Application Filing
- 2013-03-14 MX MX2014011233A patent/MX358514B/es active IP Right Grant
- 2013-03-14 CN CN201380027139.9A patent/CN104470909B/zh active Active
- 2013-03-14 EP EP13763520.7A patent/EP2828247B1/en active Active
- 2013-03-14 CA CA2868026A patent/CA2868026C/en active Active
- 2013-03-14 EA EA201491766A patent/EA028382B1/ru not_active IP Right Cessation
-
2015
- 2015-03-19 HK HK15102837.6A patent/HK1202527A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MX358514B (es) | 2018-08-24 |
CN104470909B (zh) | 2018-04-24 |
BR112014023483A2 (xx) | 2017-06-20 |
KR20140135840A (ko) | 2014-11-26 |
CA2868026A1 (en) | 2013-09-26 |
EA028382B1 (ru) | 2017-11-30 |
MX2014011233A (es) | 2014-11-25 |
EP2828247B1 (en) | 2019-01-16 |
US20150080383A1 (en) | 2015-03-19 |
WO2013142236A1 (en) | 2013-09-26 |
CN104470909A (zh) | 2015-03-25 |
JP2015517988A (ja) | 2015-06-25 |
CA2868026C (en) | 2021-02-16 |
EP2828247A4 (en) | 2015-12-16 |
EP2828247A1 (en) | 2015-01-28 |
KR102109992B1 (ko) | 2020-05-13 |
US9914722B2 (en) | 2018-03-13 |
EA201491766A1 (ru) | 2015-03-31 |
BR112014023483B1 (pt) | 2022-05-10 |
JP6219921B2 (ja) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254045B (en) | Compounds for the treatment of spinal muscular atrophy | |
HK1202069A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1200056A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1202527A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1202059A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1215399A1 (zh) | 用於治療脊髓性肌萎縮的化合物 | |
HRP20181190T1 (hr) | SPOJEVI KOJI SU KORISNI ZA LIJEČENJE AIDS-a | |
EP2872493A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
IL262611A (en) | Treatment for lipodystrophy | |
IL253421B (en) | Compounds for the treatment of fibrosis (Leifat) | |
EP2828100A4 (en) | SURFACE TREATMENT FOR AN IMPLANT SURFACE | |
EP2921120A4 (en) | ENDOSCOPE TREATMENT TOOL | |
EP2904994A4 (en) | spinal orthotic | |
EP2664286A4 (en) | ENDOSCOPE TREATMENT TOOL | |
GB201010359D0 (en) | Compounds for treating proliferative disorders | |
EP2916767A4 (en) | DEVICES FOR TREATING TEETH NECKS | |
EP2745764A4 (en) | TREATMENT TOOL FOR ENDOSCOPE | |
ZA201503005B (en) | Ingenol-derived compounds useful for treating cancer | |
GB201203180D0 (en) | Compounds for treating parvovirus infection | |
EP2926817A4 (en) | STABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS | |
HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
EP2563353A4 (en) | COMPOUNDS FOR ANTIFUNGAL TREATMENT | |
GB201215527D0 (en) | Compounds for the treatment of muscular dystrophy | |
GB201009495D0 (en) | Compounds for treating proliferative disorders |